Department of Rheumatology, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Pathology, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Cell Immunol. 2018 Jan;323:1-8. doi: 10.1016/j.cellimm.2017.11.002. Epub 2017 Nov 7.
Allogeneic stem cell transplantation (allo-SCT) offers an important curative therapy for hematological malignancies and other diseases. A number of studies have demonstrated the association of immune compositions in allografts with outcomes after allo-SCT, which promote graft engineering to improve transplant prognosis. This review summarizes the advances in investigating the correlation of the graft immune compositions with transplant outcomes in different transplant modalities, focusing on the immune subsets likely to have the greatest impact on clinical outcomes. The progress made in graft engineering in order to design novel transplant protocols, to decrease graft-versus-host disease and relapse and to improve immune recovery is also discussed. It is our belief that an adoptive immune subset transfer to improve clinical outcomes might represent a future direction.
异基因造血干细胞移植（allo-SCT）为血液系统恶性肿瘤和其他疾病提供了一种重要的治疗方法。许多研究表明，移植物中的免疫成分与 allo-SCT 后的结果有关，这促进了移植物工程学的发展，以改善移植预后。这篇综述总结了在不同移植方式中研究移植物免疫成分与移植结果相关性的进展，重点关注对临床结果影响最大的免疫亚群。还讨论了为设计新的移植方案、降低移植物抗宿主病和复发率以及改善免疫恢复而进行的移植物工程学进展。我们相信，通过过继性免疫亚群转移来改善临床结果可能代表未来的一个方向。
